KZR
Kezar Life Sciences, Inc. NASDAQ Listed Jun 21, 2018$7.37
After hrs
$7.37
+1.10%
Mkt Cap $54.3M
52w Low $3.53
95.5% of range
52w High $7.55
50d MA $7.09
200d MA $5.76
P/E (TTM)
-1.0x
EV/EBITDA
0.5x
P/B
0.8x
Debt/Equity
0.0x
ROE
-80.0%
P/FCF
-0.9x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$7.09
200d MA
$5.76
Avg Volume
74.4K
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
4000 Shoreline Court · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -1.31 | -1.99 | -52.0% | 6.20 | +17.7% | +20.2% | +19.7% | +19.4% | +19.4% | +19.4% | — |
| Nov 12, 2025 | AMC | -1.81 | -1.53 | +15.5% | 6.16 | +0.8% | -0.2% | +0.3% | +1.0% | +0.8% | +0.6% | — |
| Aug 13, 2025 | AMC | -2.15 | -1.87 | +13.0% | 3.92 | -0.5% | +1.5% | +1.3% | -1.5% | -1.0% | -0.5% | — |
| May 13, 2025 | AMC | -2.56 | -2.27 | +11.3% | 4.20 | +0.2% | -1.7% | -3.3% | -3.1% | -4.0% | -2.1% | — |
| Mar 25, 2025 | AMC | -2.71 | -2.77 | -2.2% | 5.64 | +0.2% | -8.3% | -9.0% | -12.8% | -13.5% | -20.0% | — |
| Nov 12, 2024 | AMC | -3.03 | -2.78 | +8.3% | 7.49 | -3.1% | +0.7% | +0.4% | -0.4% | -1.3% | -1.5% | — |
| Aug 13, 2024 | AMC | -3.20 | -2.80 | +12.5% | 58.00 | +3.4% | +5.2% | +7.8% | +5.7% | +5.5% | +3.6% | — |
| May 9, 2024 | AMC | -3.40 | -3.00 | +11.8% | 81.70 | -2.1% | -5.4% | -8.4% | -3.3% | -5.5% | -6.0% | — |
| Mar 14, 2024 | AMC | -3.90 | -3.50 | +10.3% | 85.00 | -0.9% | +3.5% | +2.4% | +2.5% | +4.9% | +13.5% | — |
| Nov 13, 2023 | AMC | -3.60 | -3.20 | +11.1% | 72.70 | +10.9% | +7.7% | +8.9% | +15.4% | +18.3% | +21.7% | — |
| Aug 10, 2023 | AMC | -3.30 | -3.40 | -3.0% | 205.00 | -6.3% | -26.3% | -24.4% | -24.9% | -29.3% | -32.2% | — |
| May 11, 2023 | AMC | -2.80 | -3.10 | -10.7% | 260.00 | +0.0% | +0.8% | +15.8% | +17.3% | +8.5% | +1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 17 | William Blair | Downgrade | Outperform → Market Perform | — | $4.17 | $5.66 | +35.7% | +52.5% | +51.3% | +49.4% | +48.0% | +47.5% |
| Oct 17 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $4.17 | $5.66 | +35.7% | +52.5% | +51.3% | +49.4% | +48.0% | +47.5% |
| Oct 17 | Jefferies | Downgrade | Buy → Hold | — | $4.17 | $5.66 | +35.7% | +52.5% | +51.3% | +49.4% | +48.0% | +47.5% |
| Jul 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.62 | $4.57 | -1.1% | -2.6% | -3.5% | -5.8% | -6.9% | -3.7% |
| Dec 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.29 | $6.26 | -0.5% | +3.7% | +1.4% | +2.4% | +4.3% | +8.7% |
| Dec 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $7.47 | $7.40 | -0.9% | -0.8% | -5.4% | -5.6% | -7.0% | -9.0% |
| Nov 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $7.54 | $7.54 | +0.0% | -0.3% | -1.1% | -2.0% | -2.1% | -0.7% |
| Oct 2 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.91 | $7.91 | +0.0% | +4.9% | +4.4% | +0.9% | -2.1% | -6.4% |
| Aug 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.00 | $60.00 | +3.4% | +5.2% | +7.8% | +5.7% | +5.5% | +3.6% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.00 | $63.90 | +1.4% | +0.5% | +0.3% | +4.9% | +4.4% | +6.0% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $81.70 | $80.00 | -2.1% | -5.4% | -8.4% | -3.3% | -5.5% | -6.0% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $85.00 | $84.20 | -0.9% | +3.5% | +2.4% | +2.5% | +4.9% | +13.5% |
| Dec 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $83.80 | $84.00 | +0.2% | +2.9% | +2.0% | +3.7% | +3.7% | +2.7% |
| Nov 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $91.50 | $91.50 | +0.0% | -2.4% | -5.1% | -9.2% | -8.4% | -8.4% |
| Nov 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $72.70 | $80.60 | +10.9% | +7.7% | +8.9% | +15.4% | +18.3% | +21.7% |
| Oct 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $108.00 | $106.00 | -1.9% | -15.2% | -11.4% | -7.4% | -1.9% | -8.5% |
| Oct 5 | JonesTrading | Downgrade | Buy → Hold | — | $101.00 | $100.00 | -1.0% | -7.5% | -5.3% | -9.2% | +3.0% | +6.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $114.00 | $120.00 | +5.3% | -1.8% | -5.3% | +0.9% | +3.5% | +4.4% |
| Aug 11 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $205.00 | $192.00 | -6.3% | -26.3% | -24.4% | -24.9% | -29.3% | -32.2% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $205.00 | $192.00 | -6.3% | -26.3% | -24.4% | -24.9% | -29.3% | -32.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $260.00 | $260.00 | +0.0% | +0.8% | +15.8% | +17.3% | +8.5% | +1.5% |
| May 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $260.00 | $260.00 | +0.0% | +0.8% | +15.8% | +17.3% | +8.5% | +1.5% |
| Mar 16 | William Blair | Downgrade | Outperform → Market Perform | — | $461.00 | $410.00 | -11.1% | -17.1% | -18.4% | -20.4% | -20.6% | -23.4% |
| Mar 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $461.00 | $410.00 | -11.1% | -17.1% | -18.4% | -20.4% | -20.6% | -23.4% |
| Jan 3 | Wells Fargo | Maintains | Overweight → Overweight | — | $704.00 | $707.00 | +0.4% | -1.6% | +2.1% | -2.0% | -2.8% | -9.8% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $976.00 | $1030.00 | +5.5% | +6.0% | +10.1% | +9.4% | +1.5% | +1.9% |
| Jun 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $578.00 | $1101.00 | +90.5% | +43.4% | +37.2% | +43.1% | +60.7% | +65.1% |
| May 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $552.00 | $559.00 | +1.3% | +4.2% | +9.1% | +20.1% | +6.9% | -0.5% |
| May 4 | Wells Fargo | Maintains | Overweight → Overweight | — | $1232.00 | $868.00 | -29.5% | -43.5% | -47.6% | -48.8% | -53.7% | -54.9% |
| Mar 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1531.00 | $1600.00 | +4.5% | +1.8% | -3.4% | +4.7% | +14.6% | +19.7% |
| Dec 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $1466.00 | $1477.00 | +0.8% | +0.7% | -5.4% | -7.6% | -9.2% | -15.7% |
| Nov 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $841.00 | $1198.00 | +42.4% | +37.8% | +52.2% | +57.8% | +66.1% | +71.1% |
| Jul 20 | JonesTrading | Maintains | Buy → Buy | — | $527.00 | $543.00 | +3.0% | +2.3% | +1.9% | +0.2% | +1.7% | -1.9% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $447.00 | $675.00 | +51.0% | +73.4% | +53.9% | +40.0% | +23.0% | +19.2% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $516.00 | $540.00 | +4.7% | -0.6% | +1.0% | +17.8% | +16.5% | +21.5% |
| Mar 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $346.00 | $364.00 | +5.2% | -5.8% | -13.0% | -15.6% | -18.2% | +0.9% |
| Jul 29 | H.C. Wainwright | Maintains | Buy → Buy | — | $571.00 | $600.00 | +5.1% | +1.1% | +3.0% | -1.4% | -6.3% | -8.8% |
| Jul 16 | Wells Fargo | Maintains | Outperform → Outperform | — | $1580.00 | $1603.00 | +1.5% | +2.2% | +0.8% | +5.4% | +4.4% | +2.1% |
| Jul 16 | Jefferies | Maintains | Buy → Buy | — | $1580.00 | $1603.00 | +1.5% | +2.2% | +0.8% | +5.4% | +4.4% | +2.1% |
| Jul 16 | William Blair | Maintains | Outperform → Outperform | — | $1580.00 | $1603.00 | +1.5% | +2.2% | +0.8% | +5.4% | +4.4% | +2.1% |
| Jul 16 | Cowen & Co. | Maintains | Outperform → Outperform | — | $1580.00 | $1603.00 | +1.5% | +2.2% | +0.8% | +5.4% | +4.4% | +2.1% |
No insider trades available.
SC TO-T
!!! Very High
Unknown — Tender Offer
A tender offer for AUPH and KZR suggests potential acquisition or restructuring, making these stocks volatile short-term plays where investors should evaluate the offer price versus current trading levels and regulatory approval odds.
Apr 13
8-K
Unknown — 8-K Filing
The merger agreement requires all unvested restricted stock units to vest immediately before closing, potentially diluting shareholders and increasing acquisition costs for the acquirer.
Apr 3
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Three executives departing simultaneously signals organizational instability and increases near-term execution risk for both AUPH and KZR, likely pressuring stock prices until replacement leadership is announced.
Apr 3
8-K
Unknown — 8-K Filing
Contingent value rights (CVRs) offering shareholders potential future cash payments beyond the current offer price, which could indicate undervaluation concerns or incomplete deal certainty warranting investor caution.
Mar 30
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Kaizer Aluminum completed a strategic asset acquisition that could expand production capacity or market reach, potentially boosting revenue growth and shareholder value if integration executes smoothly.
Mar 12
Data updated apr 25, 2026 6:19pm
· Source: massive.com